adminUnknown Analyst
Good morning, everyone, and welcome to the 44th Annual JPMorgan Healthcare Conference. My name is Varun, and it is my pleasure to invite on stage today Nyxoah, represented by their CEO, Olivier Taelman. Please put your hands together for Olivier.
Olivier Taelman
CEO & Executive Director
Thank you. Let me start by thanking JPMorgan for the invitation. My name is Olivier Taelman. I am the CEO of Nyxoah. Nyxoah, a medtech company offering an innovative solution by neurostimulation to help patients suffering from obstructive sleep apnea. We are listed on both Nasdaq and Euronext under the ticker NYXH. Currently, we are going through the most exciting time in company history since we have obtained in August last year, FDA approval, and we are actively launching our product to help patients in the U.S. suffering from obstructive sleep apnea.
Our vision is to make sleep simple. Now before I will walk you through the technology, the commercial updates, et cetera, I would like to start by sharing how we at Nyxoah, how we see sustained value creation. Everything starts with the addressable market. And if you look at obstructive sleep apnea, it is a huge market. There are a lot of people, and we are talking up to 450,000 to 500,000 people that are eligible for the Genio technology in the U.S. only. That represents roughly $10 billion market opportunity. If we would have been in pharma, we would talk about blockbuster potential.
Next to this, it’s also a largely underpenetrated market. Today, not more than 8% of the total eligible to treat patient population will actually get therapy. It’s a fast-growing market. And we as Nyxoah, as I was
Read the full article here
